Results 61 to 70 of about 16,189 (104)

Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.

20.500.12530/87854Current literature and a real-world study suggest that diroximel fumarate (DRF) is safer than dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS).
Casado-Ruiz, Virginia, Sánchez-Menoyo, José Luis, Iglesias, Federico, Costa-Frossard, Lucienne, Alonso-Torres, Ana, Borrega, Laura, Galán, Victoria, Oreja-Guevara, Celia, Aguirre, Clara, García-Domínguez, José Manuel, Montero-Escribano, Paloma, Cano-Orgaz, Antonio Tomás, Meca-Lallana, Virginia, Hernández-Echevarría, Luis, Forero, Lucía, Reyes-Garrido, Virginia, de Antonio, Luis A Rodríguez, González-Quintanilla, Vicente, Agüera, Eduardo, García-Rodríguez, Raquel, Caminero-Rodríguez, Ana Belén, Arzalluz-Luque, Joaquín, Riancho, Javier, Pérez-Ruiz, Domingo, Gutiérrez-Martin, Fuencisla, Castellano-Vicente, Alberto José, Téllez, Nieves, Pérez-Parra, Fernando, Romero, Carlos, Ares-Luque, Adrián, Sánchez, Octavio   +30 more
core   +1 more source

Effect of surface roughness, biofilm coverage and biofilm structure on the electrochemical efficiency of microbial cathodes [PDF]

, 2011
Biofilms of Geobacter sulfurreducens were formed under chronoamperometry at −0.5 V and −0.6 V vs. Ag/AgCl on stainless steel cathodes and tested for fumarate reduction.
A. Bergel, L. Pons, Délia, Marie-Line, Bergel, Alain, M.-L. Délia, Pons, Liz   +5 more
core   +1 more source

Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosis

Physiological Reports, Volume 12, Issue 24, December 2024.
Abstract Multiple sclerosis (MS) is a chronic neurological condition resulting in decreased aerobic capacity (peak VO2). The hemodynamic responses to peak exercise in MS are unknown. Further, it is unknown if the hemodynamic responses are due to disease or fitness.
Brooks A. Hibner, Natalia S. Lima, Sara R. Sherman, Robert W. Motl, Julio A. Chirinos, Shane Phillips, Philip S. Clifford, Anthony T. Reder, Tracy Baynard, Bo Fernhall   +9 more
wiley   +1 more source

Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry

Therapeutic Advances in Neurological Disorders
Background: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice.
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C. Salmen, Ksenija Schirduan, Tom P. A. Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K. Zettl, Melanie Peters, Clemens Warnke   +14 more
doaj   +1 more source

COVID‐19 vaccination in patients with multiple sclerosis: what you need to know – a review

Health Science Reports, Volume 7, Issue 10, October 2024.
Abstract Background The appearance of severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) initiated the COVID‐19 pandemic, resulting in millions of confirmed cases and numerous fatalities. In response, rapid vaccine development efforts were launched to mitigate the pandemic's impact.
Farhad Mahmoudi, Omid Mirmosayyeb, Elnaz Shaabani, Elham Moases Ghaffary, Flavia Nelson   +4 more
wiley   +1 more source

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses

Frontiers in Immunology
BackgroundThere is a greater risk of complications from severe COVID-19 in immunocompromised patients with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs), as well as a diminished vaccine response.MethodsIn this ...
Ryan Curtin, Ryan Curtin, Ryan Curtin, Yogambigai Velmurugu, Yogambigai Velmurugu, Yogambigai Velmurugu, Fatoumatta Dibba, Fatoumatta Dibba, Fatoumatta Dibba, Yuan Hao, Samantha Nyovanie, Samantha Nyovanie, Samantha Nyovanie, Andrea Lopez, Andrea Lopez, David Mieles, David Mieles, Courtney Ng, Courtney Ng, Courtney Ng, Katherine Perdomo, Nicole Scott, James B. Lewin, Robin L. Avila, Jen Smrtka, Yury Patskovsky, Yury Patskovsky, Yury Patskovsky, Jonathan Howard, Jonathan Howard, Gregg J. Silverman, Michelle Krogsgaard, Michelle Krogsgaard, Michelle Krogsgaard   +33 more
doaj   +1 more source

Shifting patterns of multiple sclerosis treatment in a highly prevalent United States population

Annals of Clinical and Translational Neurology, Volume 11, Issue 6, Page 1526-1534, June 2024.
Abstract Objective Our objectives were to (1) obtain the prevalence and demography of people with multiple sclerosis (MS) in a representative Colorado population, and (2) to assess the utilization of disease‐modifying therapy within this prevalent cohort.
Sue Kwon, Stefan Sillau, John R. Corboy, Kavita V. Nair, Aaron M. Carlson   +4 more
wiley   +1 more source

Herpes zoster admissions: The majority of patients are not immunised

JEADV Clinical Practice, Volume 4, Issue 1, Page 314-315, March 2025.
Mina Raahimi, Martin Hartmann
wiley   +1 more source

Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases

Therapeutic Advances in Neurological Disorders
Background: With the development of highly effective disease-modifying treatments, vaccinations are becoming increasingly important in people with neurological autoimmune diseases.
Muriel Schraad, Mathias Mäurer, Anke Salmen, Tobias Ruck, Timo Uphaus, Vinzenz Fleischer, Felix Luessi, Maria Protopapa, Falk Steffen, Nicholas Hanuscheck, Katrin Pape, Tobias Brummer, Josef Shin, Thomas Korn, Luisa Klotz, Jan D. Lünemann, Marc Pawlitzki, Martin S. Weber, Antonios Bayas, Brigitte Wildemann, Hans-Peter Hartung, Florian Then Bergh, Clemens Warnke, Uwe K. Zettl, Achim Berthele, Aiden Haghikia, Ralf Linker, Hayrettin Tumani, Sven G. Meuth, Bernhard Hemmer, Heinz Wiendl, Tania Kümpfel, Ralf Gold, Stefan Bittner, Frauke Zipp   +34 more
doaj   +1 more source

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

Neurological Research and Practice
Introduction In Multiple Sclerosis (MS), patients´ characteristics and (bio)markers that reliably predict the individual disease prognosis at disease onset are lacking.
Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, Verena S. Hoffmann, Achim Berthele, Mark Mühlau, Markus C. Kowarik, Markus Krumbholz, Makbule Senel, Verena Steuerwald, Markus Naumann, Julia Hartberger, Martin Kerschensteiner, Eva Oswald, Christoph Ruschil, Ulf Ziemann, Hayrettin Tumani, Ioannis Vardakas, Fady Albashiti, Frank Kramer, Iñaki Soto-Rey, Helmut Spengler, Gerhard Mayer, Hans Armin Kestler, Oliver Kohlbacher, Marlien Hagedorn, Martin Boeker, Klaus Kuhn, Stefan Buchka, Florian Kohlmayer, Jan S. Kirschke, Lars Behrens, Hanna Zimmermann, Benjamin Bender, Nico Sollmann, Joachim Havla, Bernhard Hemmer, the ProVal-MS study group   +37 more
doaj   +1 more source